Literature DB >> 30699424

Surgery for Prolactinomas to Date.

Michael Buchfelder1, Yining Zhao2, Sven-Martin Schlaffer2.   

Abstract

While in the past surgery for prolactinomas was a competitive option to medical treatment with dopamine agonists, to date the indications for operations are restricted to only a few specific situations. However, if a patient is intolerant to medical treatment or if the drugs are not sufficiently effective in terms of lowering prolactin levels or tumor shrinkage, surgery should always be considered. In microprolactinomas, operations can achieve excellent prolactin normalization rates. In tumors difficult to treat, the combination of surgical tumor resection and long-term medical treatment supports better control of the disease. The individual indications, results, techniques, and complications of operations for prolactinomas are briefly reviewed in this paper.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Medical treatment; Prolactinoma; Surgery; Technical advances

Mesh:

Year:  2019        PMID: 30699424     DOI: 10.1159/000497331

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  6 in total

Review 1.  The optimal numerosity of the referral population of pituitary tumors centers of excellence (PTCOE): A surgical perspective.

Authors:  Pietro Mortini; Gianluca Nocera; Francesca Roncelli; Marco Losa; Anna Maria Formenti; Andrea Giustina
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

2.  Management of prolactinomas in children and adolescents; which factors define the response to treatment?

Authors:  Ayfer Alikasifoglu; Nur Berna Celik; Zeynep Alev Ozon; Elmas Nazli Gonc; Nurgun Kandemir
Journal:  Pituitary       Date:  2021-09-13       Impact factor: 4.107

3.  Surgical Treatment of Cystic Pituitary Prolactin-Secreting Macroadenomas: A Single Center Study of 42 Patients.

Authors:  Xiang Guo; Juan Chen; Zhuo Zhang; Xueyan Wan; Kai Shu; Ting Lei
Journal:  Brain Sci       Date:  2022-05-27

4.  EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas.

Authors:  Odelia Cooper; Vivien S Bonert; Jeremy Rudnick; Barry D Pressman; Janet Lo; Roberto Salvatori; Kevin C J Yuen; Maria Fleseriu; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2021-01-23       Impact factor: 5.958

5.  The value of intraoperative MRI for resection of functional pituitary adenomas-a critical assessment of a consecutive single-center series of 114 cases.

Authors:  Christopher Beynon; Andreas Unterberg; Moritz Scherer; Paul Zerweck; Daniela Becker; Lars Kihm; Jessica Jesser
Journal:  Neurosurg Rev       Date:  2022-05-14       Impact factor: 2.800

6.  Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery.

Authors:  Grzegorz Zielinski; Marcin Ozdarski; Maria Maksymowicz; Katarzyna Szamotulska; Przemysław Witek
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-07       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.